AlfaCip: Advanced Ciprofloxacin Therapy for Severe Bacterial Infections
| Product dosage: 0.25 mcg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 30 | $2.18 | $65.26 (0%) | 🛒 Add to cart |
| 60 | $1.99 | $130.53 $119.48 (8%) | 🛒 Add to cart |
| 120 | $1.88 | $261.05 $225.91 (13%) | 🛒 Add to cart |
| 240 | $1.83 | $522.10 $439.77 (16%) | 🛒 Add to cart |
| 300 | $1.82
Best per cap | $652.63 $546.20 (16%) | 🛒 Add to cart |
| Product dosage: 0.5 mcg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 30 | $2.24 | $67.27 (0%) | 🛒 Add to cart |
| 60 | $2.04 | $134.54 $122.49 (9%) | 🛒 Add to cart |
| 120 | $1.95 | $269.08 $233.94 (13%) | 🛒 Add to cart |
| 240 | $1.90 | $538.17 $454.83 (15%) | 🛒 Add to cart |
| 300 | $1.88
Best per cap | $672.71 $565.28 (16%) | 🛒 Add to cart |
Synonyms | |||
AlfaCip (ciprofloxacin hydrochloride) represents a potent fluoroquinolone antibiotic formulation designed for the systemic treatment of complicated bacterial infections. This broad-spectrum antimicrobial agent demonstrates exceptional bioavailability and tissue penetration, making it particularly effective against gram-negative pathogens and certain gram-positive organisms. Manufactured under strict pharmaceutical standards, AlfaCip ensures consistent dosing and reliable therapeutic outcomes in both hospital and outpatient settings. Its optimized pharmacokinetic profile allows for effective bacterial eradication while maintaining an acceptable safety margin when administered according to prescribed guidelines.
Features
- Contains ciprofloxacin hydrochloride as the active pharmaceutical ingredient
- Available in 250mg, 500mg, and 750mg film-coated tablet formulations
- Exhibits broad-spectrum activity against aerobic gram-positive and gram-negative bacteria
- Features excellent oral bioavailability exceeding 70%
- Demonstrates rapid absorption with peak serum concentrations within 1-2 hours
- Shows extensive tissue penetration including prostate, lung, and skin structure distribution
- Maintains bactericidal activity through inhibition of bacterial DNA gyrase and topoisomerase IV
- Manufactured in compliance with current Good Manufacturing Practices (cGMP)
Benefits
- Provides rapid onset of action against susceptible bacterial pathogens
- Offers convenient twice-daily dosing regimen for improved patient compliance
- Demonstrates high clinical cure rates in complicated urinary tract infections
- Effective against multidrug-resistant organisms including Pseudomonas aeruginosa
- Reduces hospitalization duration through potent outpatient treatment option
- Minimizes development of resistance through concentration-dependent killing mechanism
Common use
AlfaCip is indicated for the treatment of adults with complicated urinary tract infections, including pyelonephritis, caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, Staphylococcus epidermidis, and Enterococcus faecalis. Additionally, it is prescribed for complicated intra-abdominal infections (in combination with metronidazole), acute bacterial sinusitis, chronic bacterial prostatitis, lower respiratory tract infections including nosocomial pneumonia, skin and skin structure infections, bone and joint infections, and infectious diarrhea. Healthcare providers may also consider AlfaCap for selected cases of typhoid fever and anthrax prophylaxis or treatment following confirmed or suspected exposure.
Dosage and direction
The recommended dosage of AlfaCip varies according to the type and severity of infection, renal function, and pathogen susceptibility. For complicated urinary tract infections or pyelonephritis: 500 mg orally every 12 hours for 7-14 days. For complicated intra-abdominal infections: 500 mg orally every 12 hours for 7-14 days (must be used in combination with metronidazole). For chronic bacterial prostatitis: 500 mg orally every 12 hours for 28 days. For acute bacterial sinusitis: 500 mg orally every 12 hours for 10 days. For lower respiratory tract infections: 500 mg orally every 12 hours for 7-14 days. For skin and skin structure infections: 500 mg orally every 12 hours for 7-14 days. For bone and joint infections: 500 mg orally every 12 hours for at least 4-6 weeks. Patients with renal impairment (creatinine clearance less than 30 mL/min) require dosage adjustment to 250-500 mg every 18-24 hours depending on infection severity. Tablets should be swallowed whole with a full glass of water and may be taken with or without food, though administration 2 hours before or after meals may enhance absorption. Patients should maintain adequate hydration during therapy and avoid concomitant administration with dairy products, calcium-fortified juices, or antacids containing magnesium, aluminum, calcium, or iron, which may significantly reduce absorption.
Precautions
Patients prescribed AlfaCip should be monitored for tendon inflammation or rupture, which may occur during or after completion of therapy, particularly in elderly patients, those with renal impairment, or those concurrently using corticosteroids. Discontinue immediately if pain, inflammation, or tendon rupture occurs. Neurological adverse effects including seizures, increased intracranial pressure, dizziness, and tremors have been reported—use with caution in patients with known or suspected central nervous system disorders. Peripheral neuropathy characterized by pain, burning, tingling, numbness, and/or weakness may occur rapidly and potentially become irreversible. Photosensitivity reactions may develop; patients should avoid excessive sunlight or artificial UV light and discontinue therapy at first sign of skin erythema. Blood glucose disturbances, including symptomatic hypoglycemia, have been reported, particularly in diabetic patients receiving concurrent oral hypoglycemic agents or insulin. Clostridium difficile-associated diarrhea may range from mild to life-threatening colitis—discontinue if diarrhea develops. Patients should be advised that ciprofloxacin may prolong the QT interval in some individuals, potentially leading to torsades de pointes—avoid use in patients with known QT prolongation, uncorrected hypokalemia, or concurrent use of other QT-prolonging medications. Psychiatric adverse reactions including anxiety, agitation, insomnia, depression, and suicidal thoughts have been reported.
Contraindications
AlfaCip is contraindicated in patients with known hypersensitivity to ciprofloxacin, other quinolones, or any component of this formulation. Concomitant administration with tizanidine is absolutely contraindicated due to potentially dangerous potentiation of hypotensive and sedative effects. Use is contraindicated in patients with history of tendon disorders related to fluoroquinolone administration. The medication is contraindicated in pediatric patients (except for specific indications such as complicated urinary tract infections, pyelonephritis, or post-exposure anthrax treatment where no alternative exists), during pregnancy (Category C), and nursing mothers due to potential for arthropathy in developing joints and other serious adverse effects in infants. Patients with known myasthenia gravis should not receive AlfaCip due to potential for exacerbation of muscle weakness and respiratory compromise.
Possible side effect
The most frequently reported adverse reactions (≥1%) include nausea (5.2%), diarrhea (2.3%), vomiting (2.0%), abdominal pain/discomfort (1.7%), headache (1.2%), and restlessness (1.1%). Less common but potentially serious adverse effects include tendonitis and tendon rupture (particularly Achilles tendon), peripheral neuropathy, central nervous system effects (dizziness, seizures, increased intracranial pressure, anxiety, confusion, depression, insomnia), QT interval prolongation and ventricular arrhythmias, hypersensitivity reactions (anaphylaxis, rash, photosensitivity), hematologic abnormalities (leukopenia, neutropenia, anemia), hepatic enzyme elevation and hepatitis, blood glucose disturbances, Clostridium difficile-associated diarrhea, and crystalluria. Musculoskeletal side effects may include arthralgia, myalgia, and gait disturbance. Ophthalmologic effects including vision disturbances, diplopia, and altered color perception have been reported rarely.
Drug interaction
AlfaCip demonstrates several clinically significant drug interactions. Concurrent administration with antacids containing magnesium, aluminum, calcium, or iron; sucralfate; didanosine; or multivitamins containing zinc may substantially reduce ciprofloxacin absorption—separate administration by at least 2 hours before or 4 hours after these products. Ciprofloxacin may increase serum concentrations of theophylline, caffeine, and tizanidine, potentially leading to toxicity—monitor levels and adjust dosages accordingly. Concomitant use with other QT-prolonging agents (antiarrhythmics, antipsychotics, antidepressants, macrolides) may increase risk of torsades de pointes. NSAIDs may enhance CNS stimulation and seizure risk. Probenecid may decrease renal clearance of ciprofloxacin, increasing serum levels. Oral anticoagulants (warfarin) may have enhanced effects—monitor INR closely. Ciprofloxacin may alter phenytoin levels requiring monitoring. Concurrent use with corticosteroids may increase risk of tendon rupture. Hypoglycemic agents may require dosage adjustment due to potential for altered glucose levels.
Missed dose
If a dose of AlfaCip is missed, patients should take it as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should never take a double dose to make up for a missed one, as this may increase the risk of adverse effects. Maintaining consistent blood levels is important for antibacterial efficacy, so patients should try to adhere to the prescribed dosing schedule as closely as possible. If multiple doses are missed or uncertainty exists about how to proceed, patients should consult their healthcare provider or pharmacist for guidance.
Overdose
In the event of acute overdose, symptoms may include nausea, vomiting, diarrhea, abdominal pain, crystalluria, hematuria, CNS excitation (seizures, confusion, tremors), renal impairment, and QT prolongation. Management should include gastric lavage or emesis induction if ingestion occurred within 2 hours, followed by administration of activated charcoal. Adequate hydration should be maintained to prevent crystalluria. ECG monitoring is recommended for at least 24 hours to detect QT prolongation. Seizures may require benzodiazepine administration. Hemodialysis or peritoneal dialysis removes less than 10% of the drug and is not expected to significantly enhance elimination. Treatment is primarily supportive and symptomatic with close monitoring of renal function and neurological status. Specific antidotes are not available.
Storage
Store AlfaCip tablets at controlled room temperature between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep in the original container with the lid tightly closed to protect from moisture and light. Do not store in bathroom cabinets where humidity levels may fluctuate. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Properly discard any unused medication that is no longer needed or has expired through medication take-back programs or according to local disposal guidelines. Do not flush medications down the toilet unless specifically instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. AlfaCip is a prescription medication that should be used only under the supervision of a qualified healthcare professional. The prescribing physician should be consulted for diagnosis and treatment decisions. Patients should not initiate, discontinue, or change dosage without medical supervision. While every effort has been made to ensure accuracy, manufacturers may update product information periodically. Healthcare providers should reference the most current official prescribing information before making treatment decisions. Individual patient responses may vary, and not all side effects or interactions are listed here.
Reviews
Clinical studies demonstrate that AlfaCip achieves clinical cure rates of 85-95% in complicated urinary tract infections when caused by susceptible organisms. In trials involving complicated intra-abdominal infections, combination therapy with metronidazole showed success rates exceeding 80% at test-of-cure visit. For chronic bacterial prostatitis, microbiological eradication rates reached 75% at 4-6 weeks post-therapy. Healthcare providers report satisfactory outcomes in appropriately selected patients, particularly noting its effectiveness against Pseudomonas aeruginosa and other multidrug-resistant gram-negative organisms. Patient satisfaction surveys indicate appreciation for the twice-daily dosing convenience, though some report gastrointestinal side effects that typically resolve after completion of therapy. Post-marketing surveillance continues to monitor the benefit-risk profile in real-world clinical practice.